Antibody Fragment Conjugates

This approach uses a large molecular weight polyethylene glycol conjugated to antibody fragments. The specially designed PEG then becomes part of the antibody fragment Fc. Since the antibody fragment is more like a biologic, this conjugation has a branched architecture with either stable or degradable linkage.

Where might this conjugation technique be beneficial?

• Parenterally administered molecules
• Need to enhance pharmacokinetics
  • The target of this conjugation is improved toxicity profile, extended half-life, and ease of synthesis with the antibody

Why use the Antibody Fragment Conjugates?

• Reduce antigenicity
• Reduce glomerular filtration rate
• Identify to proper linkage site to facilitate the re-production of identical conjugates from batch to batch
• Must still retain antigen-binding affinity and recognition

Technology Overview »